A 6-week, prospective, randomized, double-blind, double-dummy phase IV clinical trial designed to evaluate the efficacy of an aggressive multi-risk factor management strategy with caduet versus a guideline-based approach in achieving blood pressure and lipid goals in hypertensive subjects with additional risk factors

Trial Profile

A 6-week, prospective, randomized, double-blind, double-dummy phase IV clinical trial designed to evaluate the efficacy of an aggressive multi-risk factor management strategy with caduet versus a guideline-based approach in achieving blood pressure and lipid goals in hypertensive subjects with additional risk factors

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2009

At a glance

  • Drugs Amlodipine; Amlodipine/atorvastatin
  • Indications Dyslipidaemias; Hypertension
  • Focus Therapeutic Use
  • Acronyms TOGETHER
  • Sponsors Pfizer
  • Most Recent Events

    • 09 May 2009 Primary endpoint results presented at the 24th Annual Scientific Meeting of the American Society of Hypertension
    • 26 Nov 2008 Actual patient number reported as 245 by ClinicalTrials.gov.
    • 18 May 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top